KALV (KalVista Pharmaceuticals) Forward P/E Multiple

Corporate company logo of KalVista Pharmaceuticals Inc (KALV)

Anticipation of late-stage clinical trial results for an oral treatment to manage angioedema attacks serves as the primary growth trigger for KalVista Pharmaceuticals (KALV). The forward P/E ratio of KalVista Pharmaceuticals (KALV) on the GURU.Markets chart, where the metric value is 33.90, confirms the stability of a business creating convenient, high-margin tablets. This approach establishes a unique therapeutic ecosystem, transforming the developments of KalVista Pharmaceuticals (KALV) into an indispensable standard of care for rare pathologies.

Projected Price to Earnings: KalVista Pharmaceuticals, Inc. (KALV) for 07/04/2022 - 06/21/2026

Analytical breakdowns for KalVista Pharmaceuticals

Summary company analytics:kalvista.com
Product sample of KalVista Pharmaceuticals

The fate of KalVista Pharmaceuticals (KALV) depends on the clinical trial results of its drug for hereditary angioedema. The company's forward P/E ratio compares the current share price with projected net income for future periods. This indicator measures market expectations, demonstrating the extent of the premium paid for future earnings. This chart reflects investor reaction to regulatory risks and capital requirements, allowing for an assessment of the fairness of the market capitalization.

Competitors of KalVista Pharmaceuticals (KALV)

Projected Price to Earnings ARGX (Argenx)|BNTX (BioNTech Group) - Future Price to Earnings Multiple|Forward P/E Multiple ABVX (Abivax SA)|Market Cap to Projected Earnings admabiologics.com (ADMA)|PTGX - Future Price to Earnings|Immunovant Inc (IMVT) - Projected Price to Earnings|Kiniksa Corp (KNSA) - Future Price to Earnings|Projected Price to Earnings Grifols, S.A.|Projected Price to Earnings ADPT|Forward P/E Multiple celldex.com|Future Price to Earnings Aurinia Pharma (AUPH)|BioCryst Pharmaceuticals - Price to Future Earnings Ratio|Forward P/E Multiple VERA (veratx.com)|Dianthus Pharma (DNTH) - Projected Price to Earnings Ratio|PHVS - Future Price to Earnings|ABCL - Forward P/E Multiple|Tourmaline (TRML) - Future Price to Earnings|Precigen - Future Price to Earnings Multiple|PHAR (Pharming Group NV) - Forward P/E Multiple|Forward P/E Multiple Nektar Therapeutics|Future Price to Earnings Upstream Bio Inc (UPB)|Forward P/E Multiple zenasbio.com (ZBIO)|Future Price to Earnings Immunome Corp IMNM|Forward P/E Multiple Gossamer Bio Inc GOSS|SEPN - Future Price to Earnings|Market Cap to Projected Earnings Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Projected Price to Earnings|Price to Expected Earnings Ratio RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - Forward P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Cap to Future Earnings Ratio|Future Price to Earnings engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Future Price to Earnings Multiple|Aerovate Therapeutics - Projected Price to Earnings|Future Price to Earnings Multiple ACRS|Kyverna Therapeutics, Inc - Forward P/E Multiple|Price to Expected Earnings Ratio TLSA|CABA: Forward P/E Multiple|Projected Price to Earnings Ventyx Bio|Future Price to Earnings Theratechnologies, Inc.|Projected Price to Earnings Ratio Avalo Therapeutics AVTX|Forward P/E Multiple ELDN|AGEN (Agenus, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Projected Price to Earnings Ratio|ATYR: Projected Price to Earnings|adagene.com (ADAG) - Projected Price to Earnings|Ikena Oncology (IMA) - Future Price to Earnings|Projected Price to Earnings Shattuck Labs, Inc.|Future Price to Earnings equilliumbio.com|Projected Price to Earnings connectbiopharm.com (CNTB)|Forward P/E Multiple IMUX|Market Cap to Projected Earnings Atara Bio|Future Price to Earnings InflaRx N.V. IFRX|X4 Pharmaceuticals - Future Price to Earnings|ACET: Projected Price to Earnings|Future Price to Earnings Multiple CELU (celularity.com)|INMB: Forward P/E Multiple|BRNS: Market Cap to Future Earnings Ratio|KZR (Kezar Life Sciences, Inc.) - Forward P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Market Cap to Projected Earnings|Forward P/E Multiple AKTX|Future Price to Earnings ENLV (Enlivex Therapeutics Ltd)|Future Price to Earnings Q32 Bio Inc. QTTB|GOVX - Projected Price to Earnings|EDSA - Future Price to Earnings|Projected Price to Earnings Ratio iBio|CARM: Forward P/E Multiple|Price to Expected Earnings Ratio XTLB (XTL Biopharmaceuticals, Ltd.)|Future Price to Earnings boltbio.com|Forward P/E Multiple HCW Biologics|Forward P/E Multiple APVO|AIM - Projected Price to Earnings Ratio|Forward P/E Multiple ADTX (Aditxt Inc.)|Market Cap to Projected Earnings GRI Bio, Inc. (GRI)|XRTX - Future Price to Earnings|reshapelifesciences.com (HIND) - Projected Price to Earnings|REVB: Forward P/E Multiple|Indaptus Therapeutics, Inc. - Future Price to Earnings Multiple|Future Price to Earnings Scinai|Projected Price to Earnings Ratio CalciMedica, Inc. CALI|Future Price to Earnings Affimed NV (AFMD)|Forward P/E Multiple Allakos Inc (ALLK)|Future Price to Earnings hookipapharma.com HOOK|Forward P/E Multiple IGM Biosciences, Inc. IGMS|iTeos Pharma - Forward P/E Multiple|OCEA - Forward P/E Multiple|TCBP: Forward P/E Multiple|Third Harmonic Bio - Future Price to Earnings Multiple